The race among countries and companies to develop efficacious vaccines and therapeutics for the COVID-19 is ongoing fast, with many trials underway. Among this, cell-based therapy is focused on moderate to severe phases of COVID-19, and there have been promising outcomes. Mesenchymal stem cells (MSCs) due to their pro/anti-inflammatory and immune-modulatory behavior, Natural Killer (NK) cells thanks to their capacity of lysing virus-infected cells and regulate the resulting immune response, Dendritic cells thanks to immunotherapy and cell-based vaccine engineering, SARS-CoV2-specific T cells due to stimulate and promote the immune system and MSC-derived exosomes because of cell-free therapy and beneficial manufacturing aspects, hold great promises for cell-based therapy applications for treating COVID-19 and similar viral infections. Moreover, recently, an innovative approach to COVID-19 based on engineered human MSC has been introduced, which is continuously evacuated and degraded by the body’s immune system during the antigen recognition process. However, the economic situation of governments and nations, and the cost of therapeutics influence the clinical approaches to manage and exit from this pandemic. This summary describes cell-based clinical trials and the cost-utility aspects of cell therapy. In this regard, limited clinical studies have been reported; while, several clinical trials have been approved for starting phases 2 and 3 of their trials for treating COVID-19 patients with acute respiratory distress syndrome. Regarding the cost of cell therapy, many believe that the high cost of cell-based therapy will decrease substantially. Hence, there are hopes that cellular therapy can be approved soon for the treatment of viral diseases such as COVID-19.

国家和公司之间为 COVID-19 开发有效疫苗和疗法的竞赛正在进行中，许多试验正在进行中。其中，基于细胞的治疗主要针对 COVID-19 的中重度阶段，并取得了可喜的成果。间充质干细胞 (MSC) 具有促/抗炎和免疫调节行为，自然杀伤 (NK) 细胞具有溶解病毒感染细胞并调节由此产生的免疫反应的能力，树突状细胞具有免疫疗法和细胞基于疫苗工程的 SARS-CoV2 特异性 T 细胞（由于刺激和促进免疫系统）和 MSC 衍生的外泌体（由于无细胞疗法和有益的制造方面），对于用于治疗 COVID-19 的基于细胞的疗法应用前景广阔和类似的病毒感染。而且，最近，一种基于工程化人类 MSC 的 COVID-19 创新方法被引入，该方法在抗原识别过程中不断被人体免疫系统排出和降解。然而，政府和国家的经济状况以及治疗成本会影响管理和摆脱这种流行病的临床方法。本摘要描述了基于细胞的临床试验和细胞疗法的成本效用方面。在这方面，报告的临床研究有限；同时，几项临床试验已获批准开始其治疗 COVID-19 急性呼吸窘迫综合征患者的试验的第 2 期和第 3 期。关于细胞疗法的成本，许多人认为基于细胞疗法的高昂成本将大幅下降。因此，